Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe The positive CHMP opinion is based on
Read More